XATRAL 10 Milligram Tablet Prolonged Release
Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
Caracteristicilor produsului
(SPC)
27-05-2024
Unele documente pentru acest produs nu sunt disponibile în prezent, puteți trimite o solicitare la serviciul nostru pentru clienți și vă vom anunța de îndată ce vom putea să le obținem.
Trimite cerere.
Trimite cerere.
Ingredient activ:
ALFUZOSIN HYDROCHLORIDE
Disponibil de la:
Chemilines Healthcare (Ireland) Limited
Codul ATC:
G04CA01
INN (nume internaţional):
ALFUZOSIN HYDROCHLORIDE
Dozare:
10 Milligram
Forma farmaceutică:
Tablet Prolonged Release
Tip de prescriptie medicala:
Product subject to prescription which may be renewed (B)
Zonă Terapeutică:
Alpha-adrenoreceptor antagonists
Statutul autorizaţiei:
Authorised
Data de autorizare:
2013-08-02
Caracteristicilor produsului
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Xatral 10mg Prolonged Release Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10mg alfuzosin hydrochloride
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet, prolonged release.
_Product imported from France and Italy:_
Round biconvex three layer tablet; one white layer between two yellow layers.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of the functional symptoms of benign prostatic hypertrophy.
Adjunctive therapy with urethral catheterisation for Acute Urinary Retention related to BPH.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Xatral 10mg Prolonged Release Tablets are for oral administration.
Xatral 10mg Prolonged Release Tablets should be swallowed whole.
BPH: The recommended dose is one 10mg tablet once daily to be taken after a meal.
AUR: One 10mg tablet daily after a meal to be taken from the first day of catheterisation.
Paediatric population:
Efficacy of Xatral has not been demonstrated in children aged 2 to 16 years (see section 5.1). Therefore, Xatral is not
indicated for use in paediatric population.
4.3 CONTRAINDICATIONS
Hypersensitivity to alfuzosin or any component. History of orthostatic hypotension. Combination with other -
blockers. Hepatic insufficiency.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
As with all alpha
1
-blockers in some subjects, in particular patients receiving antihypertensive medications or nitrates.
In some subjects postural hypotension may develop, with or without symptoms (dizziness, fatigue, sweating) within a
few hours following administration. These effects are usually transient, occur at the beginning of treatment and do not
usually prevent the continuation of treatment. In such cases, the patient should lie d
Citiți documentul complet
